《福泰制药Vertex Pharmaceuticals Inc. (VRTX) 2005年10-K年度报告「NASDAQ」.pdf》由会员分享,可在线阅读,更多相关《福泰制药Vertex Pharmaceuticals Inc. (VRTX) 2005年10-K年度报告「NASDAQ」.pdf(209页珍藏版)》请在三个皮匠报告上搜索。
1、FORM 10-K VERTEX PHARMACEUTICALS INC/MA(Annual Report)Filed 3/16/2006 For Period Ending 12/31/2005Address130 WAVERLY STREETCAMBRIDGE,Massachusetts 02139-4242Telephone616-577-6000 CIK0000875320IndustryBiotechnology&DrugsSectorHealthcareFiscal Year12/31 QuickLinks-Click here to rapidly navigate throug
2、h this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 10-K Commission file number 000-19319 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter)Registrants telephone number,including area code(617)444-6100 Securities register
3、ed pursuant to Section 12(b)of the Exchange Act:None Securities registered pursuant to Section 12(g)of the Exchange Act:Common Stock,$0.01 Par Value Per Share Rights to Purchase Series A Junior Participating Preferred Stock (Title of class)(Mark One)?ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF T
4、HE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31,2005 or?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Massachusetts 04-3039129(State or other jurisdiction of incorporation or organization)(I.R.S.Empl
5、oyer Identification No.)130 Waverly Street Cambridge,Massachusetts 02139-4242(Address of principal executive offices)(Zip Code)Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes?No?Indicate by check mark if the registrant is not
6、required to file reports pursuant to Section 13 or Section 15(d)of the Exchange Act.Yes?No?Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter perio